Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prismasol is a sterile, pre-mixed electrolyte and bicarbonate solution used as a replacement fluid or dialysate in Continuous Renal Replacement Therapy (CRRT). Developed by Baxter (and managed by its kidney care spinoff, Vantive Health), it is indicated for pediatric and adult patients to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. It is also used in cases of drug poisoning to facilitate the removal of dialyzable substances. The solution typically comes in a dual-chamber bag containing electrolytes such as sodium, calcium, magnesium, potassium, and chloride, along with a bicarbonate buffer and sometimes glucose. These components are mixed immediately before administration to the extracorporeal circuit to maintain physiological homeostasis in critically ill patients with acute kidney injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prismasol.